Clinical value of Bovine Pulmonary Surfactant combined with nasal-continuous positive airway pressure ventilation in the treatment of neonatal respiratory distress syndrome
LONG Yu-yu
Department of Neonatology,Zigong First People′s Hospital,Sichuan Province,Zigong 643000,China
Abstract：Objective To analyze the clinical value of Bovine Pulmonary Surfactant combined with nasal-continuous positive airway pressure ventilation (NCPAP) in the treatment of neonatal respiratory distress syndrome (NRDS).Methods From March 2018 to October 2019,88 cases of NRDS diagnosed and treated in our department were randomly divided into the observation group and the control group according to the envelope method,44 cases in each group.Both groups were treated with NCPAP,and the observation group was treated with Bovine Pulmonary Surfactant in addition.The clinical symptom improvement,the blood gas analysis index,ventilator ventilation time,oxygen therapy time,hospitalization time and the incidence of complications between the two groups were compared.Results The disappearance time of cyanosis and dyspnea in the observation group was shorter than that in the control group,the difference was statistically significant (P<0.05).The blood gas analysis indexes both improved in the two groups after treatment,and the blood oxygen partial pressure of the observation group was higher than that of the control group,and the partial pressure of carbon dioxide was lower than that of the control group,the differences were statistically significant (P<0.05).The ventilator ventilation time,oxygen therapy time and hospitalization time of the observation group were shorter than those of the control group,the differences were statistically significant (P<0.05).There was no significant difference in the total incidence of complications between the two groups (P>0.05).Conclusion Compared with using NCPAP alone,Bovine Pulmonary Surfactant combined with NCPAP is more effective in the treatment of NRDS,promoting the earlier elimination of clinical symptoms,improving blood gas analysis results,shortening ventilation time,and reducing the risk of complications.So it is worth promoting in clinical application.
龙俞宇. 牛肺表面活性物质联合经鼻气道正压通气治疗新生儿呼吸窘迫综合征的临床价值[J]. 中国当代医药, 2020, 27(30): 4-7.
LONG Yu-yu. Clinical value of Bovine Pulmonary Surfactant combined with nasal-continuous positive airway pressure ventilation in the treatment of neonatal respiratory distress syndrome. 中国当代医药, 2020, 27(30): 4-7.
京公网安备 11010502046607号